Product Description
MK-0493 is a novel, potent, and selective agonist of the melanocortin receptor 4 (MC4R), one of the best-validated genetic targets and considered one of the most promising for the development of antiobesity therapeutics.Ê (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19741604/)
Mechanisms of Action: MCR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Obesity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00482196 |
NCT00482196 | P2 |
Completed |
Obesity |
2006-03-01 |
2022-05-04 |
Treatments |
|
NCT00482638 |
NCT00482638 | P2 |
Completed |
Obesity |
2004-10-29 |
2022-05-04 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/01/2022 |
News Article |
Terray Therapeutics Expands Leadership Team with Fez Ujjainwalla, PhD as Head of Business and Adam D. Hughes, PhD as Head of Chemistry |